Publication:
Prognostic significance of c-erbB2 overexpression in patients with metastatic gastric cancer

dc.contributor.buuauthorBayrak, Mehmet
dc.contributor.buuauthorÖlmez, Ömer Fatih
dc.contributor.buuauthorKurt, Ender
dc.contributor.buuauthorÇubukçu, Erdem
dc.contributor.buuauthorEvrensel, Türkkan
dc.contributor.buuauthorKanat, Özkan
dc.contributor.buuauthorManavoǧlu, Osman
dc.contributor.departmentTıp Fakültesi
dc.contributor.departmentOnkoloji Ana Bilim Dalı
dc.contributor.orcid0000-0002-9732-5340
dc.contributor.researcheridAAJ-1027-2021
dc.contributor.scopusid57210190959
dc.contributor.scopusid26435400000
dc.contributor.scopusid7006207332
dc.contributor.scopusid53986153800
dc.contributor.scopusid6603942124
dc.contributor.scopusid55881548500
dc.contributor.scopusid6602587152
dc.date.accessioned2022-11-21T12:28:54Z
dc.date.available2022-11-21T12:28:54Z
dc.date.issued2013-04
dc.description.abstractOverexpression of the gene c-erbB2, which encodes a receptor tyrosine kinase, has been associated with prognosis and response to therapy in several solid tumors. This study was designed to test whether c-erb-B2 overexpression can be related to prognosis of patients with metastatic gastric cancer. Between 2005 and 2010, 46 cases of metastatic gastric cancer were evaluated immunohistochemically for c-erb-B2 overexpression. Overall survival (OS) and time-to-progression (TTP) served as the main outcome measures. c-erbB2 was overexpressed in 19 (41.3 %) cases and 8 patients (17.4 %) had a c-erbB2 score of 3+ (a strong complete membrane staining observed in > 10 % of the tumor cells). c-erbB2 expression was not associated with the clinicohistological characteristics of the study participants. The mean OS was 11.48 +/- A 1.03 months, whereas the mean TTP was 8.28 +/- A 0.8 months. Compared with patients with a score of 2+ or less (n = 38), those with a c-erbB2 score of 3+ (n = 8) had both a significantly lower OS (15.55 +/- A 1.63 vs. 8.22 +/- A 0.88 months, respectively, p < 0.05) and TTP (10.72 +/- A 1.81 vs. 6.11 +/- A 0.61 months, respectively, p < 0.05). After allowance for potential confounders, Cox regression analysis identified a c-erbB2 score of 3+ as an independent predictor of both OS (hazard ratio = 1.9; 95 % confidence interval = 1.1-3.7, p < 0.05) and TTP (hazard ratio = 1.8; 95 % confidence interval = 1.1-4.1, p < 0.05). Our results suggest that c-erbB-2 overexpression may have a prognostic significance in patients with metastatic gastric cancer.
dc.identifier.citationBayrak, M. vd. (2013). "Prognostic significance of c-erbB2 overexpression in patients with metastatic gastric cancer". Clinical and Translational Oncology, 15(4), 307-312.
dc.identifier.endpage312
dc.identifier.issn1699-048X
dc.identifier.issue4
dc.identifier.pubmed22911549
dc.identifier.scopus2-s2.0-84876494901
dc.identifier.startpage307
dc.identifier.urihttps://doi.org/10.1007/s12094-012-0921-0
dc.identifier.urihttps://link.springer.com/article/10.1007/s12094-012-0921-0
dc.identifier.urihttp://hdl.handle.net/11452/29523
dc.identifier.volume15
dc.identifier.wos000316260600009
dc.indexed.scopusScopus
dc.indexed.wosSCIE
dc.language.isoen
dc.publisherSpringer
dc.relation.journalClinical and Translational Oncology
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi
dc.rightsinfo:eu-repo/semantics/closedAccess
dc.subjectOncology
dc.subjectC-erbB2
dc.subjectGastric cancer
dc.subjectMetastasis
dc.subjectImmunohistochemistry
dc.subjectPrognosis
dc.subjectExpression
dc.subjectTrastuzumab
dc.subjectBreast
dc.subjectHer2
dc.subject.emtreeEpidermal growth factor receptor 2
dc.subject.emtreeAdult
dc.subject.emtreeAged
dc.subject.emtreeArticle
dc.subject.emtreeC erbB2 gene
dc.subject.emtreeCancer growth
dc.subject.emtreeCancer prognosis
dc.subject.emtreeCancer survival
dc.subject.emtreeClinical article
dc.subject.emtreeClinical feature
dc.subject.emtreeControlled study
dc.subject.emtreeDisease association
dc.subject.emtreeFemale
dc.subject.emtreeGene overexpression
dc.subject.emtreeHistopathology
dc.subject.emtreeHuman
dc.subject.emtreeHuman tissue
dc.subject.emtreeMale
dc.subject.emtreeMetastasis
dc.subject.emtreeOverall survival
dc.subject.emtreePrediction
dc.subject.emtreeScoring system
dc.subject.emtreeStomach cancer
dc.subject.emtreeTime to progression
dc.subject.meshAdult
dc.subject.meshAged
dc.subject.meshFemale
dc.subject.meshHumans
dc.subject.meshImmunohistochemistry
dc.subject.meshMale
dc.subject.meshMiddle aged
dc.subject.meshNeoplasm metastasis
dc.subject.meshPrognosis
dc.subject.meshReceptor, erbB-2
dc.subject.meshStomach neoplasms
dc.subject.meshSurvival analysis
dc.subject.meshTumor markers, biological
dc.subject.meshUp-regulation
dc.subject.meshYoung adult
dc.subject.scopusCancer; Trastuzumab; Gastroesophageal Junction
dc.subject.wosOncology
dc.titlePrognostic significance of c-erbB2 overexpression in patients with metastatic gastric cancer
dc.typeArticle
dc.wos.quartileQ4
dc.wos.quartileQ4
dspace.entity.typePublication
local.contributor.departmentTıp Fakültesi/Onkoloji Ana Bilim Dalı
local.indexed.atPubMed
local.indexed.atWOS
local.indexed.atScopus

Files

License bundle

Now showing 1 - 1 of 1
Placeholder
Name:
license.txt
Size:
1.71 KB
Format:
Item-specific license agreed upon to submission
Description: